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Abstract
Rationale Recent findings show lowered brain-derived neuro-
trophic factor (BDNF) levels in major depressive disorder
(MDD). Exposure to stressful life events may (partly) underlie
these BDNF reductions, but little is known about the effects of
early or recent life stress on BDNF levels. Moreover, the effects
of stressful events on BDNF levels may in part be conditional
upon a common variant on the BDNF gene (Val66Met; RS6265),
with the Met allele being associated with a decrease in activity-
dependent secretion of BDNF compared to the Val allele.
Methods We investigated cross-sectionally in 1,435 indi-
viduals with lifetime MDD the impact of childhood abuse
(CA) and recent life events on serum BDNF levels and
assessed whether the impact of these events was moderated
by the BDNF Val66Met polymorphism.
Results Overall, BDNF Met carriers had reduced serum
BDNF levels when exposed to CA in a dose-dependent
way. Moreover, exposure to recent life events was also
associated with decreases in BDNF levels, but this was
independent of BDNF Val66Met. Moreover, when not
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exposed to CA, Met carriers had higher BDNF levels than
the Val/Val individuals, who did not show decreases in
BDNF associated with CA. Finally, these findings were
only apparent in the MDD group without comorbid anxiety.
Conclusions These gene–environment interactions on
serum BDNF levels suggest that Met carriers are
particularly sensitive to (early) stressful life events,
which extends previous findings on the moderating role
of the BDNF Val66Met polymorphism in the face of
stressful life events.
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Introduction
Major depressive disorder (MDD) is one of the most
common psychiatric disorders, which involves dysregu-
lation of affect, motivation, appetite, sleep, and cogni-
tive dysfunctions, resulting in impairments in several
aspects of life. An accumulating body of research
indicates that MDD is often the result of the interplay
between genetic vulnerability and environmental factors
(Kendler 2005). In particular, child abuse (CA) is a
significant etiological factor in the development and
persistence of MDD across the life cycle (Charney 2004;
Heim and Nemeroff 2001; McLaughlin et al. 2010;
Spinhoven et al. 2010). Moreover, exposure to stress
during adulthood (for example, divorce and job loss) often
precipitates or exacerbates depressive symptoms (Kendler
et al. 1999). In some instances, stressful events in
adulthood interact with stressful events that occurred early
in life to contribute to the process of stress sensitization
(Post 2007).
Given its major contribution to the burden of disease, it
is important to identify underlying biological mechanisms
that might lead from stress exposure to MDD. One of the
neurobiological changes that may be triggered by both
chronic and acute stress is a downregulation of brain-
derived neurotrophic factor (BDNF). The neurotrophin
BDNF is a critical regulator of the formation, plasticity,
and integrity of neurons in brain circuits that regulate
emotion (Angelucci et al. 2005; Duman and Monteggia
2006). In animals, exposure to stress early in life (for
example, repeated maternal separation) has been found to
induce a relative decrease in the expression of BDNF
and to subsequent neuronal atrophy and degeneration in
the hippocampus and the cortex, which can persist into
adulthood (Murakami et al. 2005; Roceri et al. 2004;
Song et al. 2006; Smith et al. 1995). According to the
“neurotrophic hypothesis of depression,” these reductions
in BDNF expression may account for the pathophysiology
of MDD (Duman and Monteggia 2006). Consistent with
this idea, several studies found decreased central (Karege
et al. 2005) and peripheral levels of BDNF (Molendijk
et al. 2010; Sen et al. 2008) in patients with MDD. More
specifically, in line with the animal models, one study
found lowered plasma BDNF in depressed women with a
history of childhood physical neglect compared to non-
abused depressed women and controls (Grassi-Oliveira
et al. 2008). A study among bipolar patients reported
similar reductions in serum BDNF levels in patients
exposed to stressful life events (Kauer-Sant’Anna et al.
2007).
A common single-nucleotide polymorphism (SNP) on
the BDNF gene is Val66Met. Val66Met refers to a valine
(Val) to methionine (Met) insertion at codon 66 (Egan
et al. 2003). This SNP affects intracellular processing and
secretion of BDNF, with the Met allele being associated
with a decrease in activity-dependent secretion of BDNF
compared to the Val allele (Egan et al. 2003). Most studies
have compared carriers of a Met allele (Val/Met) with
individuals who are homozygous for the Val allele (Val/
Val) because individuals who are homozygous for the Met
allele (Met/Met) are rare in Caucasians (approximately
4%). In general, these studies have shown that Met
carriers have lower hippocampal gray matter (Bueller
et al. 2006; Pezawas et al. 2004) and poorer episodic
memory performance (Egan et al. 2003) compared to
individuals homozygous for the Val allele. Moreover,
several studies have reported that Met carriers are more
vulnerable to the effects of CA compared to individuals
who are homozygous for the Val allele in terms of
depressive symptoms (Kaufman et al. 2006; Wichers
et al. 2008) and hippocampal gray matter (Gatt et al.
2009).
Whereas variations on the BDNF gene seem to play an
important role in MDD, little is known on how variations
on the BDNF polymorphism Val66Met may influence
serum BDNF levels of individuals who have been exposed
to CA and/or recent negative life events. A closer
examination of the impact of CA and recent life stress
and the moderating role of variations on the BDNF
polymorphism Val66Met on blood-derived BDNF levels
may help to elucidate the neurobiological changes that
underlie the susceptibility of developing MDD after
exposure to stressful life events. Therefore, using data from
the Netherlands Study of Depression and Anxiety
(NESDA, see Penninx et al. 2008), we investigated, cross-
sectionally, the impact of CA and recent life events on
serum BDNF levels in a large sample of individuals with
lifetime MDD (n=1,435) and assessed whether the impact
of these stressful life events was moderated by variations on
the BDNF Val66Met polymorphism (comparing Met
carriers to homozygous Val carriers). Based on findings in
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animals and humans, we hypothesized that both CA and
recent life events would reduce serum BDNF levels,
particularly in Met carriers of the Val66Met polymorphism.
Materials and methods
Participants
Participants were derived from NESDA (for details on the
design, objectives, and protocol of NESDA, see Penninx
et al. 2008). In brief, NESDA is a prospective cohort study
(N=2,981) that recruited subjects with a current MDD
and/or an anxiety disorder, patients with MDD and/or an
anxiety disorder in remission, and healthy controls without
a history or current MDD or anxiety disorder in specialized
mental health care, primary care, and the general popula-
tion. A general inclusion criterion was an age of 18 through
65 years. Excluded were individuals with a primary
diagnosis of psychotic, obsessive compulsive, bipolar, or
severe addiction disorder (requiring care in specialized
addiction clinics). A second exclusion criterion was not
being fluent in Dutch. At baseline, participants provided
blood and underwent a medical examination. The study
protocol was approved by the Ethical Review Board of the
VU University Medical Center and by local review boards
of each participating institute. After full information about
the study was provided, written informed consent was
obtained from all participants.
From the NESDA baseline sample, we selected 1,435
participants (48.1%), with a mean age of 42.2 years (±12.4)
and 30.7% (n=440) males. To investigate individuals with
a vulnerability to MDD, our selection was based on the
following criteria: (1) participants had to have a current or
lifetime diagnosis of MDD; (2) genomic data, data on
serum BDNF levels, and measurements of CA and recent
stress had to be available; and (3) participants had to be of
North-European descent.
DSM-IV diagnoses (APA 1994) of MDD and anxiety
disorders (generalized anxiety, social phobia, panic with or
without agoraphobia, or agoraphobia without history of panic)
were determined by means of the Composite Interview
Diagnostic Instrument (CIDI; Wittchen et al. 1991) that was
administered by trained research staff. The CIDI has high
reliability (Wacker et al. 2006) and validity (Wittchen et al.
1991). Depression symptom severity was assessed using the
Inventory of Depressive Symptoms Self-Report version (Rush
et al. 1996). The use of antidepressants was gauged on by self-
report and drug container observation.
CA was assessed retrospectively using a semistruc-
tured childhood trauma interview, previously used in the
Netherlands Mental Health Survey and Incidence Study
(de Graaf et al. 2004a, b). In this interview, participants
were asked whether they had experienced before the age
of 16 years one of the following types of trauma:
emotional neglect, psychological, and physical and/or
sexual abuse. Emotional neglect was described as
“Nobody ever listened to you at home, your problems
were ignored, you had the feeling not being able to find
any attention or support from your parents.” Psychological
abuse was described as “You were verbally abused,
unjustly punished, your brothers and sisters were favored,
but no bodily harm was done.” Physical abuse was defined
as “Being kicked, hit with or without an object, or being
physically maltreated in any other way.” Sexual abuse was
defined as “Being touched sexually by anyone against
your will, or being forced to touch anyone sexually.” After
an affirmative answer, details on the frequency of these
events and the perpetrators involved were asked for.
Because of the large overlap between emotional neglect
and emotional abuse, the two types of abuse were merged
together as “emotional abuse.” Answers were coded as
zero, one, two, or three reported types of CA. The mean
number (±standard deviation (SD)) of CA types was 1.12
(±1.15), with 42.7% (n=613) reporting no CA, 21.6%
(n=310) reporting one type of CA, 17.1% (n=246)
reporting two types of CA, and 18.5% (n=266) reporting
three types of CA. For the main analysis of variance
(ANOVA), the presence of CA was defined as 0 versus ≥1
type of CA. For dose–response analyses, individuals were
divided into three categories: individuals reporting no CA,
one type of CA, and two or more types of CA.
The occurrence of 12 recent stressful life events (“recent
stress”) was assessed using the List of Threatening Events
Questionnaire (LTE-Q; Brugha et al. 1985; Brugha and
Cragg 1990). These events reflect the presence of life
stressors during the past year, such as serious illness and
injury, death of close friend or relative, unemployment,
major financial loss, and loss of important relationships.
The LTE-Q has good test–retest reliability, high agree-
ment between participant and informant ratings, and
good agreement with interview-based ratings (Brugha
and Cragg 1990). Answers were coded as the total number
of life events. The mean number (±SD) of reported
stressful life events was 0.68 (±1.0), with 58.4%
(n=838) reporting no life events, 23.6% (n=338) report-
ing one event, 12.1% (n=173) reporting two events, 4.5%
(n=64) reporting three events, 0.6% (n=9) reporting four
events, 0.6% (n=9) reporting five events, 0.2% (n=3)
reporting six events, and 0.1% (n=1) reporting seven
events. For the main analyses, “recent stress” was defined
as 0 versus ≥1 incidents of stressful life events during the
preceding year, whereas for the dose–response analyses,
individuals were divided into three groups: individuals
reporting no life event, one life event, and two or more life
events in the past year.
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Genotyping
Genotyping of the subjects was performed by Perlegen
Sciences using high oligonucleotide arrays (Mountain View,
CA, USA). For detailed descriptions on the procedures
according to which genotyping was performed, we refer to
Boomsma et al. (2008). The Val66Met polymorphism
(Dibisnp 6265) was extracted from whole genome data
using PLINK software (http://pngu.mgh.harvard.edu/~pur
cell/plink). Val66Met was in the equilibrium as stated by
Hardy and Weinberg (P=.28). Moreover, genotype frequen-
cies (Val66Val 65.5%, Val66Met 32.5%, and Met66Met 2%)
were similar to those reported in previous studies on
Caucasian populations (Gatt et al. 2009; Lang et al. 2009).
Individuals who were homozygous for the Met allele were
merged with the heterozygous individuals into a group of
Met carriers (n=495) and compared to homozygous Val
carriers (n=940).
Serum BDNF measurements
Fifty milliliters of blood was withdrawn into vacuum
tubes between 07:30 a.m. and 09:30 a.m. after an
overnight fast. Following blood collection, serum was
separated and stored at −85°C until it was assayed.
BDNF protein levels were measured using the Emax
ImmunoAssay system from Promega according to the
manufacturer’s protocol (Madison, WI, USA). Greiner
Bio-One high-affinity 96-well plates were used. Serum
samples were diluted 100 times, and the absorbency was
read in duplicate using a Bio-Rad Benchmark microplate
reader at 450 nm. Serum BDNF protein levels were
expressed in nanograms per milliliter. The intra-assay
and inter-assay coefficients of variation were within 3%
and 9%, respectively. Prior to analyses, BDNF values
that were three SD above the mean (n=5, 0.35%) were
trimmed to a value of the mean plus three SDs. One
BDNF value (0.07%) was below the reliable detection
limit of the ELISA kit of 1.56 ng/ml and was set at the
lower detection limit of 1.56 ng/ml.
Statistical analysis
ANOVAs and χ2 tests were used to determine between-
group differences in demographical and clinical features
(see Table 1).
Estimates of the main and interaction effects of CA,
recent stress, and Val66Met on serum levels of BDNF
were performed using 2 (CA: yes/no)×2 (recent stress:
yes/no)×2 (BDNF Val66Met: Val/Val vs. Met carriers)
ANOVA. CA and recent stress were entered as dichoto-
mous (yes/no) variables in order to have a maximal
number of subjects in each cell. Since gender, age, years
of education, symptom severity of depression, presence of
current MDD vs remitted MDD, presence of a current
comorbid anxiety disorder, use of an antidepressant, exact
time of morning blood withdrawal, and the duration of
serum storage have been discussed as potential sources of
between-subject variation in BDNF levels (Begliuomini
et al. 2008; Sen et al. 2008; Trajkovska et al. 2007), we
statistically controlled for their possible confounding
effects by adding these variables as covariates to the
analysis. Significant interactions were followed up by
independent t tests.
Secondly, because recent studies suggest that the
symptomatology and causal pathways for MDD without
comorbid anxiety disorder may be quite distinct to those for
MDD with comorbid anxiety disorder(s) (see Gatt et al.
2009), we repeated the same 2 (CA: yes/no)×2 (recent
stress: yes/no)×2 (BDNF Val66Met: Val/Val vs. Met
carriers) ANOVA in participants with (lifetime) MDD
without comorbid anxiety (MDD−, n=401) and individuals
with (lifetime) MDD and comorbid anxiety disorders
(MDD+ANX, n=1,033), separately.
Finally, to asses dose–response relations between CA
and recent stress and BDNF levels, additional ANOVAs
were conducted in the case of significant main effects of
CA and/or recent stress or interactions with BDNF
Val66Met, based on three categories (no CA or recent life
events vs one type of CA or recent life event vs two or
more types of CA or recent life events).
Computations were performed in PASW version 18.0
(PASW, Chicago, IL, USA). Statistical significance was set
at P<.05 (two-sided). Effect sizes were presented as
Cohen’s d (1988).
Results
Demographics
Table 1 shows the demographical and clinical character-
istics by Val66Met, reported history of CA, and recent
stressful life events. Exposure to CA and recent stressful
life events was independent of BDNF genotype (P=.13 and
P=.74, respectively). Exposure to recent stressful life
events tended to be reported somewhat more often in
individuals with a history of CA (P=.07). Individuals who
were homozygous for the Val allele had more years of
education compared to individuals who carried a Met allele.
Individuals who reported CA were of older age and more
likely to be female, to have a current episode of MDD, to
have more chronic MDD, to have greater symptom severity
of MDD, and to have a comorbid anxiety and alcohol use
disorder compared to individuals who did not report CA.
Individuals reporting recent life events were of younger
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age, had less years of education, and were more likely to
smoke, to have a current episode of MDD, to have chronic
MDD, to have greater symptom severity, and to have a
comorbid anxiety disorder (see Table 1). No other main
effects nor Val66Met×CA, Val66Met×recent stress, or
Val66Met×CA×recent stress interactions were found.
Impact of childhood abuse, recent stress, and Val66Met
on serum BDNF levels
Using a 2 (CA: yes/no)×2 (recent stress: yes/no)×2 (BDNF
Val66Met: Val/Val vs. Met carriers) ANOVA on serum
BDNF levels, we found no main effect of CA (P=.38) nor
a main effect of Val66Met on BDNF levels (P=.33), but
BDNF Val66Met moderated the effects of CA on serum
BDNF levels (F1, 1,416=5.57, P=.018, see Fig. 1). Met
carriers reporting CA had significantly lower levels of
BDNF compared to Met carriers that did not report CA
(F1, 506=4.19, P=.041, d=0.19), whereas individuals report-
ing CA who were homozygous for the Val allele had similar
levels of BDNF compared to homozygous Val carriers
without CA (P=.12). Furthermore, in individuals reporting
no CA, Met carriers had higher levels of BDNF compared to
homozygous Val carriers (F1, 629=3.88, P=.049, d=0.19),
while in the CA group, Met carriers had similar levels of
BDNF compared to homozygous Val carriers (P=.22).
Exposure to recent stressful life events did not affect BDNF
levels (P=.79). No other interaction effects were found
(all Ps>.10).
Dose–response associations between CA and BDNF
To investigate a dose–response association between CA and
BDNF levels in the Met carriers versus the Val/Val group,
Table 1 Demographic and clinical characteristics by brain-derived neurotrophic factor genotype (Val66Met) and exposure to child abuse and
recent stressful events (N=1,435)
Val66Val (n=940) Val66Met (n=495) P value
No abuse (n=388) Abuse (n=552) No abuse (n=225) Abuse (n=270)
No recent
stress
(n=237)
Recent
stress
(n=151)
No recent
stress
(n=309)
Recent
stress
(n=243)
No recent
stress
(n=138)
Recent
stress
(n=87)
No recent
stress
(n=154)
Recent
stress
(n=116)
Male, % 38.0 32.5 25.9 26.3 31.2 37.9 31.8 27.6 <.05a
Age (years) 42.3±12.8 38.5±13.7 44.1±11.4 42.2±11.8 41.8±13.3 39.5±12.7 44.4±11.7 41.7±12.5 <.01a, b
Education (years) 12.3±3.1 12.1±3.2 12.2±3.4 11.8±3.3 12.1±3.0 11.2±3.1 12.0±3.1 11.4±3.3 .06
Body mass index 26.2±4.9 25.1±4.4 25.7±5.3 26.0±5.3 25.3±4.9 25.4±4.8 26.5±5.4 25.7±5.6 .23
Smoker, % 31.3 42.9 38.0 41.8 34.1 48.8 3.3 48.2 <.01b
Alcohol dependent, % 13.9 13.6 22.0 23.9 18.8 14.9 20.8 29.3 <.01a
Emotional abuse, % NA NA 93.8 94.8 NA NA 94.4 96.3 .79
Physical abuse, % NA NA 27.8 34.9 NA NA 27.1 40.4 <.05b
Sexual abuse, % NA NA 38.2 29.3 NA NA 29.2 38.5 .09
>1 event of abuse, % NA NA 63.1 64.2 NA NA 53.9 67.2 .10
>1 event of recent stress, % NA 47.7 NA 43.2 NA 58.6 NA 32.8 <.05a
Current MDD
(6 months), %
46.4 54.3 57.9 68.3 59.4 54.0 54.5 69.8 <.001a, b
Chronic MDDc 24.3 22.7 28.1 33.2 21.5 28.2 24.6 37.4 <.05a, b
MDD severity (IDS) 22.1±12.8 24.3±12.4 27.7±13.2 31.2±12.4 24.0±13.5 23.2±13.5 26.7±13.1 29.7±11.6 <.001a, b
Comorbid anxietyd, % 30.0 28.5 41.4 49.8 33.3 33.2 35.1 46.6 <.01a, b
Antidepressant usee, % 35.0 33.1 39.3 42.8 30.4 26.4 39.6 44.0 <.05a
IDS inventory of depressive symptoms, MDD major depressive disorder
a There is a difference at P<.05 between the no abuse group and the abuse group
c There is a difference at P<.05 between the no recent stress group and the recent stress group
c Symptoms were considered chronic if they were present for at least 24 months during the last 5 years
d Included a diagnosis of social phobia, panic disorder with and without agoraphobia, agoraphobia, or generalized anxiety disorder during the last six month
e Included the use of noradrenergic and specific serotonergic antidepressants, serotonin and norepinephrine reuptake inhibitors, selective serotonin reuptake
inhibitors, St. John’s wort, and tricyclic antidepressants
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additional 3 (categories of CA: no CA (n=613) vs. one type
of CA (n=310) vs. two or more types of CA (n=512))×2
(BDNF Val66Met: homozygous Val/Val vs. Met carriers)
ANOVAwas conducted. An interaction was found between
CA categories and Val66Met (F2, 1,418=2.99, P=.05). Post
hoc comparisons showed that BDNF levels were only low
in Met carriers when participants reported two or more
types of CA compared to no CA (P=.032), but not when
they reported one type of CA (P=.51), while in the
homozygous Val carriers, no main effect of CA categories
was found (P=.29, data not shown).
MDD without comorbid anxiety versus MDD
with comorbid anxiety
MDD without comorbid anxiety
We repeated the 2 (CA: yes/no)×2 (recent stress: yes/no)×2
(BDNF Val66Met: Val/Val vs. Met carriers) ANOVA on
serum BDNF levels in individuals with an (lifetime) MDD
without a comorbid anxiety disorder (MDD−, n=402, see
Fig. 2). In the MDD− group, recent stress did affect BDNF
levels (F1, 383=7.19, P=.008, d=0.29), indicating lower
BDNF levels in individuals reporting one or more recent
stressful life events (mean±SD=8.24±3.20) compared to
those who did not report negative life events (mean±SD=
9.16±3.06). Moreover, the interaction between CA and
BDNF Val66Met was also present in the MDD− group
(F1, 383=9.77, P=.002), with Met carriers who report CA
having significantly lower serum levels of BDNF compared
to Met carriers who did not report CA (F1, 138=10.03,
P=.002, d=0.44), whereas individuals reporting CA who
were homozygous for the Val allele even had somewhat
higher levels of BDNF compared to homozygous Val
carriers without CA (F1, 258=3.82, P=.052, d=0.23).
Moreover, Met carriers with a reported history of CA
showed low BDNF levels compared to homozygous Val
carriers with reported CA (F1, 173=7.45, P=.007, d=0.45),
while Met carriers reporting no CA had higher BDNF
levels compared to the nonabused homozygous Val carriers
(F1, 223=5.34, P=.022, d=0.23). There were no other main
or interaction effects in the MDD− group.
Dose–response associations between recent stress
and BDNF in the MDD− group
To evaluate whether there was a dose–response associ-
ation between the number of reported recent life events
and BDNF levels, an additional ANOVA was conducted
on the three categories of recent stress: no (n=232)
vs one recent life event (n=92) vs two or more life events
(n=78), which confirmed the effect of recent stress
(F2, 388=3.17, P=.04). However, post hoc comparisons
showed that BDNF was not affected in a dose-dependent
way: whereas individuals reporting one life event had
lower BDNF levels (mean±SD, 8.19±3.09) than those
reporting no life event (mean±SD, 9.11±3.06; P=.018;
d=0.30), the group reporting two or more life events
(mean±SD, 8.53±3.35) did not differ from the group
reporting no or one life event (both Ps>.10).
Dose–response associations between CA categories
and BDNF in the MDD− group
To investigate a dose–response association between CA and
BDNF levels in Met carriers versus the homozygous Val
MDD-group (without comorbid anxiety)
6
7
8
9
10
11
No recent stress Recent stress No recent stress Recent stress
No Childhood Abuse Childhood Abuse
se
ru
m
 B
D
N
F 
le
ve
ls
 (n
g/m
l)
Val66Met
Val66Val
* * 
*  
Fig. 2 Mean values of serum levels of BDNF by exposure to
Childhood Abuse (CA), recent stressful events, and BDNF Val66Met
in the group of lifetime MDD-patients without comorbid anxiety
disorders (n=402)
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Fig. 1 Mean values of serum levels of BDNF by exposure to
Childhood Abuse (CA), recent stressful events, and BDNF Val66Met
in the total group of life-time MDD-patients (n=1,435)
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group, an additional 3 (categories of CA: no CA (n=225) vs
one type of CA (n=81) vs two or more types of CA
(n=96))×2 (BDNF Val66Met: homozygous Val/Val vs. Met
carriers) ANOVAwas conducted (see Fig. 3). An interaction
was found between CA categories and Val66Met (F3, 383=
6.47, P<.0001), indicating that BDNF levels decrease in
Met carriers with increasing types of CA (F3, 132=5.00,
P=.003), while in the homozygous Val carriers, no main
effect of CA categories was found (P=.11). Post hoc
comparisons showed that BDNF levels were only low in
Met carriers when participants reported two or more types of
CA compared to no CA (P=.001, d=0.63), but not when
they reported one type of CA (P=.11). Moreover, Met
carriers only had lower BDNF levels when reporting two or
more types of CA compared to the Val/Val group that reported
two or more types of CA (P=.006, d=0.66), but not when
reporting one type of CA (P=.46). Furthermore, a main
effect of Val66Met also emerged (F3, 383=5.56, P=.019),
with Met carriers having lower BDNF levels compared to
Val/Val individuals, regardless of CA categories.
MDD with comorbid anxiety
The results of the same ANOVA in the MDD+ANX group
showed a main effect of recent stress on BDNF levels
(F1, 1,014=4.14, P=.042, d=0.16). In contrast to the
findings in the MDD− group, recent stress exposure was
associated with elevated BDNF levels (mean±SD, 9.26±3.8)
compared to not being exposed to recent stressful events
(mean±SD, 8.47±3.4). Moreover, recent stress tended to
interact with BDNF Val66Met (F1, 1,014=3.04, P=.082). No
other main or interaction effects were significant in the
MDD+ANX group.
Dose–response associations between recent stress
categories and BDNF in the MDD+ANX group
To evaluate whether there was a dose–response association
between the number of reported life events in the Val/Met
vs. the Val/Val, an additional 3 (categories of recent stress:
no (n=606) vs one recent life event (n=246) vs two or
more life events (n=181))×2 (BDNF Val66Met: Val/Val vs.
Met carriers) ANOVA was conducted. Here, only a trend
for life events categories was found (F2, 1,016=2.33,
P= .098) and no interaction with BDNF Val66Met
(P=.29). When comparing the means for the three recent
stress groups post hoc, only individuals reporting one life
event (mean±SD, 9.58±4.00) had higher BDNF levels than
those reporting no life events (mean±SD, 8.98±3.42; P=.031),
whereas the group reporting two or more life events (mean±
SD, 9.14±3.42) did not differ from the group reporting 1 or
no life event (both Ps>.10).
Discussion
The main new result of this study is that the impact of CA
on serum BDNF levels appears to be dependent on
variations on the BDNF Val66Met polymorphism, at least
in individuals with (lifetime) MDD without comorbid
anxiety. In BDNF Met carriers, exposure to CA was
associated with reduced serum levels of BDNF, and these
differences were most pronounced in Met carriers who also
reported negative life event(s) in the past year (see Fig. 2).
In addition, these BDNF reductions associated with CA
were linear in nature, so that BDNF levels were lowest in
Met carriers reporting two or more types of CA. Moreover,
these associations were not accounted for by the presence
of a current diagnosis of MDD or by other potentially
confounding factors, such as gender, or the use of an
antidepressant, as these factors were added as covariates in
the analyses and did not differ between the homozygous
Val/Val and the Met carriers. The Val/Val group, on the
other hand, did not show reductions in BDNF levels related
to CA, and in the MDD group without comorbid anxiety,
BDNF levels were even higher in Val/Val participants
reporting CA. Taken together, these findings are in line
with the idea that Met carriers are more sensitive to stress-
induced downregulation of BDNF.
A second main finding is that exposure to stressful events
that occurred in the past year reduced BDNF levels,
independent of variations on the BDNF Val66Met polymor-
phism, at least in the MDD group without comorbid anxiety.
These results extend the finding of two previous studies
showing lowered BDNF levels in bipolar patients reporting
negative life events (Kauer-Sant’Anna et al. 2007), and in
women with high risk of depression reporting recent life
MDD-group (without comorbid anxiety)
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events (Trajkovksa et al. 2008). In the group with comorbid
anxiety, recent stress exposure was associated with increased
BDNF levels, however. Moreover, while CA was associated
with reduced BDNF in the Met carriers, BDNF levels were
not affected by CA in the comorbid group. These findings
seem to suggest that comorbid anxiety disorder may
counteract the downregulation of BDNF associated with
CA and recent stressful event. So far, it is unclear how this
relates to the symptomatology of MDD with and without
comorbid anxiety, particularly because CA has specifically
been linked to comorbidity of MDD and anxiety disorders
(Hovens et al. 2009). Moreover, some studies have associ-
ated the Val/Val polymorphism with patterns of anxiety,
rather than with depressive symptoms (Gatt et al. 2009), but
in the group with comorbid anxiety disorders, we did not
find any indications that Val/Val individuals have lower
BDNF levels.
Although it should be taken into account that this is a
cross-sectional study, preventing causal inferences about
the impact of CA, it is remarkable that exposure to CA,
which occurred in many individuals more than 25 years
ago, is associated with decreased BDNF levels, at least in
Met carriers without comorbid anxiety disorders. These
reductions of serum BDNF levels in individuals with
reported CA suggest that exposure to chronic stress during
childhood may lead to a long-lasting downregulation of the
neurotrophic system, which might be further reduced by
recent stressful events. These results extend the findings of
previous studies showing lower levels of peripheral BDNF
in patients with current MDD and a history of CA (Grassi-
Oliveira et al. 2008). Since variations at the Val66Met locus
were not taken into account in this study, it remains unclear
whether the effects of CA were mainly driven by Met
carriers, as might be expected on the basis of our results.
The finding of reduced BDNF levels in Met carriers is
also of interest when considered in the context of previous
findings, indicating that Met carriers are particularly
vulnerable to the impact of CA with respect to depressive
symptoms (Gatt et al. 2009; Kaufman et al. 2006; Wichers
et al. 2008) and enhanced loss of hippocampal-lateral
prefrontal gray matter (Gatt et al. 2009), given that low
BDNF levels are associated with MDD (Sen et al. 2008).
Moreover, reductions in BDNF expression can have a direct
impact on neuronal growth and plasticity in frontohippo-
campal networks (Murakami et al. 2005; Roceri et al. 2004;
Song et al. 2006; Smith et al. 1995). It should be noted that, in
our sample, no associations were found between Met carriers
and higher depression severity after CA, however, which is
consistent with some recent studies (see Aguilera et al. 2009;
Nederhof et al. 2010). Definitely, longitudinal studies are
needed to further unravel the developmental trajectories
relating exposure to CA and recent life events to low BDNF
levels and altered brain structures and functioning.
One other interesting observation is that variations on
the BDNF Val66Met polymorphism itself were not directly
associated with variations in BDNF levels even though,
among individuals reporting no CA, Met carriers had
higher BDNF levels compared to homozygous Val
carriers. Very few studies in humans investigated the
association between the BDNF Val66Met polymorphism
and serum BDNF levels. One study in psychological
healthy individuals also reported enhanced serum BDNF
levels in Met carriers compared to Val/Val individuals
(Lang et al. 2009). Two other studies did not find an
association between the Val66Met polymorphism and
variations in peripheral BDNF levels, not in a sample of
depressed patients (Duncan et al. 2009) nor among healthy
twins with and without a co-twin history of affective
disorder (Vinberg et al. 2009), even though in this last
study, BDNF levels were higher among a subgroup of Met
carriers at high risk for depression or bipolar disorder.
Taken together, findings regarding associations between
the Val66Met polymorphism and variations in peripheral
BDNF levels in humans are mixed. This could be due to
the fact that, in previous studies, neither CA nor exposure
to recent stressful events has been taken into account.
Furthermore, this might also be related to the fact that the
direct associations between Val66Met and BDNF levels, if
anything, appear to be rather small in individuals reporting
no CA (in our study d=0.19) and thus can only be
detected in large samples.
In sum, this study has shown that CA is associated with
reduced BDNF levels in Met carriers with lifetime MDD
(without comorbid anxiety), whereas serum BDNF levels of
Val/Val carriers do not seem to be affected by CA. A number
of limitations should be taken into account when evaluating
these findings. First, the reliability of participants’ recall of
events from childhood may vary, given the long time gap
between occurrence and recall. Self-reported CA requires
caution when interpreting the results, althoughGoodman et al.
(1999) observed good reliability among psychiatrically ill
women. Related to this, one cannot rule out that the
association between CA or recent stress and low BDNF
levels in individuals with lifetime MDD could (in part) be
spurious, in the sense that individuals with a current
depressed mood might have low BDNF levels and also
experience life events in a (more) negative way, without
these factors being directly related to each other. We do not
consider this possibility very likely, however. First of all, we
have previously shown that, in the NESDA sample, the
association between negative life events and depression is
independent of current mood state (Spinhoven et al. 2010).
Moreover, in all statistical analyses, we added current vs
remitted MDD as a covariate, and the associations between life
events and BDNF remain statistically significant when taking
current mood state into account. A longitudinal design would
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be optimal to assess whether predifferences–postdifferences in
serum BDNF are directly affected by stressful events. Another
limitation is that we assessed serum BDNF levels, which may
not be a direct measure of central BDNF, even though previous
studies in animals showed that BDNF can cross the blood–
brain barrier in both directions (Pan et al. 1998) and a strong
association has been reported between central and peripheral
BDNF levels (Karege et al. 2002). A third limitation is that
we only assessed the Val66Met variant, whereas there are
more loci on the BDNF gene that might be associated with
variations in serum BDNF levels. Moreover, gene×gene
interactions, particularly with the 5HTT-LPR polymorphism,
were not addressed in this study, whereas these interactions
have been shown to be relevant in predicting depression
severity in combination with CA in some studies (see
Kaufman et al. 2006; Wichers et al. 2008), although not in
others (Gatt et al. 2009).
Despite the considerations mentioned above, the findings
of this study highlight the importance of investigations that
focus on integrating candidate genes, BDNF levels, and
environmental stressors and provide new and important
evidence to suggest that a chain of events, commencing with
G×E interactions and their impact on (set points of) BDNF,
may lead to low BDNF levels in patients with lifetime MDD.
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